Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SLDB vs ARVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLDB Captures Overall Composite Edge (36.5 SELL vs 52.9 HOLD), While ARVN Leads 4–1 on Growth & Valuation Pillars

SLDB Overall Winner 6-Pillar Tally: SLDB 1 – 4 ARVN (1 Tie) Matrix Metrics: SLDB 4 – 6 ARVN

As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. SLDB trades at $6.57 (N/M Forward P/E, 0.0% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin).

  • Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY).
  • Technical & Structure Timing Caution: SLDB is currently in a Breakdown options structure phase (RSI 47.8); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLDB vs ARVN
SLDB NASDAQ Head-to-Head Winner
Solid Biosciences Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.57
-4.02% 1D
Market Cap $781.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.14β · 76% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 15.0 Fund 36.0 Flow 70.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.8 · SMA20: $6.49 · SMA50: $7.12
ARVN NASDAQ
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57

6-Pillar Scorecard Institutional Category Breakdown (SLDB 1 – 4 ARVN)

Columns: Metric · SLDB · ARVN
1. Valuation Multiples ARVN
Forward P/E N/M 17.9x
Trailing P/E N/M 17.9x
PEG Ratio N/M N/M
EV / Revenue N/M 1.3x
2. Growth & Scale ARVN
Revenue Growth (YoY) -100.0% -98.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $275M
Market Cap $781.3M $449.9M
3. Profitability & Quality SLDB
Gross Margin N/A 96.7%
Operating Margin 0.0% -10.1%
Net Profit Margin 0.0% -3.5%
Return on Equity (ROE) -76.9% -1.8%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$200M -$160M
Cash Flow Margin N/A -58.0%
Net Cash / Leverage $106M Net Cash $81M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ARVN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 103.7% (15th %ile) 108.7% (25th %ile)
Put/Call OI Skew 0.08x (Call-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLDB (4) vs ARVN (6)
Institutional Metric SLDB ARVN Criterion Row Edge
Market Capitalization
Scale
$781.3M $449.9M Larger Scale SLDB
Trailing P/E Ratio
Valuation
N/M 17.9x Lower Multiple ARVN
Forward P/E Ratio
Valuation
N/M 17.9x Lower Multiple ARVN
Revenue Growth (YoY)
Growth
-100.0% -98.8% Higher Growth ARVN
Operating Margin (TTM)
Profitability
0.0% -10.1% Higher Margin SLDB
Net Profit Margin
Profitability
0.0% -3.5% Higher Margin SLDB
Return on Equity (ROE)
Capital Efficiency
-76.9% -1.8% Higher ROE ARVN
52-Week Range Position
Momentum
33% ($4–$11) 5% ($6–$15) Stronger Trend SLDB
Beta / 30D Volatility
Risk Regime
2.14β · 76% Vol 1.40β · 66% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
36.5 / 100 (SELL) 52.9 / 100 (HOLD) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
N/A $275M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 96.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$200M ($106M Net Cash) -$160M ($81M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLDB +22.02 pp
SLDB: +18.72% · ARVN: -3.3%
3M Horizon ARVN +0.49 pp
SLDB: -27.7% · ARVN: -27.21%
6M Horizon SLDB +24.07 pp
SLDB: +0.84% · ARVN: -23.23%
1Y Horizon SLDB +86.07 pp
SLDB: +52.67% · ARVN: -33.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SLDB Revenue ARVN Revenue SLDB Op. Margin ARVN Op. Margin Margin Leader
FY2018 N/A $10M N/A -306.3% ARVN
FY2019 N/A $20M N/A -281.4% ARVN
FY2020 N/A $20M N/A -554.1% ARVN
FY2021 $10M $50M -530.5% -403.4% ARVN
FY2022 $10M $130M -1315.2% -200.3% ARVN
FY2023 N/A $80M N/A -511.5% ARVN
FY2024 N/A $260M N/A -95.0% ARVN
FY2025 N/A $260M N/A -45.1% ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLDB BREAKDOWN
93d in phase · OBV ACCUMULATION
Current IV 103.7%
IV Percentile 15th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SLDB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLDB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $781.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SLDB vs ARVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Solid Biosciences Inc. (SLDB) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (36.5/100 SELL vs. 52.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while ARVN wins 4–1 across the 6-pillar growth and valuation breakdown. SLDB trades at $6.57 (N/M Forward P/E, 0.0% operating margin) versus ARVN at $6.74 (17.9x Forward P/E, -10.1% operating margin). Composite vs. Pillar Nuance: While ARVN currently prints a higher short-term Unified Composite Score (52.9/100 HOLD vs. SLDB 36.5/100 SELL), SLDB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -10.1% operating margin) and revenue trajectory (-100.0% vs. -98.8% YoY). Technical & Structure Timing Caution: SLDB is currently in a Breakdown options structure phase (RSI 47.8); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARVN leads the Growth & Scale pillar: SLDB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARVN at -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SLDB cumulative revenue shifted +0.0% while ARVN shifted +2500.0%. In operating R&D and SG&A reinvestment, SLDB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARVN.

ARVN screens cheaper on headline valuation multiples. SLDB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLDB (-76.9% ROE) versus ARVN (-1.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SLDB carries 103.7% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.14β · 76% Vol realized risk). By comparison, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.